Skip to main content

Table 1 Characteristics of the included patients with first primary kidney cancer

From: Competing risk analysis of cardiovascular/cerebrovascular death in T1/2 kidney cancer: a SEER database analysis

Characteristics Group 1 (Alive) Group 2 (CCD) Group 3 (KCD) Group 4 (OE) p-value
Age at diagnosis      < 0.001
 1–50 8366 (25.74%) 156 (5.05%) 316 (9.84%) 453 (7.18%)  
 51–58 8512 (26.19%) 369 (11.95%) 577 (17.96%) 838 (13.28%)  
 59–65 6804 (20.93%) 475 (15.39%) 591 (18.4%) 1091 (17.28%)  
 66–73 5544 (17.06%) 687 (22.25%) 635 (19.77%) 1480 (23.45%)  
 over 75 3280 (10.09%) 1400 (45.35%) 1093 (34.03%) 2450 (38.81%)  
Marital status      < 0.001
 Sinlge/divorce/widow 10,464 (32.19%) 1442 (46.71%) 1322 (41.16%) 2833 (44.88%)  
 Marry 22,042 (67.81%) 1645 (53.29%) 1890 (58.84%) 3479 (55.12%)  
Race      < 0.001
 White 26,784 (82.40%) 2482 (80.40%) 2670 (83.13%) 5219 (0.10%)  
Asian/Pacific Islander 1701 (5.23%) 112 (3.63%) 163 (5.07%) 224 (3.55%)  
 Black 3759 (11.56%) 474 (15.35%) 352 (10.96%) 809 (12.82%)  
 American Indian/Alaska Native 262 (0.81%) 19 (0.62%) 27 (0.84%) 60 (0.95%)  
Sex      < 0.001
 Female 12,938 (39.8%) 1159 (37.54%) 1177 (36.64%) 2385 (37.79%)  
 Male 19,568 (60.2%) 1928 (62.46%) 2035 (63.36%) 3927 (62.21%)  
T (AJCC 6th)      < 0.001
 I 28,286 (87.02%) 2668 (86.43%) 2039 (63.48%) 5398 (85.52%)  
 II 4220 (12.98%) 419 (13.57%) 1173 (36.52%) 914 (14.48%)  
N (AJCC 6th)      < 0.001*
 0 32,389 (99.64%) 3063 (99.22%) 2992 (93.15%) 6233 (98.75%)  
 I 86 (0.26%) 21 (0.68%) 151 (4.7%) 64 (1.01%)  
 II 31 (0.10%) 3 (0.10%) 69 (2.15%) 15 (0.24%)  
M (AJCC 6th)      < 0.001
 0 32,506 (100%) 3087 (100%) 3212 (100%) 6312 (100%)  
 I 0 0 0 0  
Tumour size      < 0.001
  ≤ 3 cm 13,379 (41.16%) 1057 (32.24%) 492 (15.32%) 2182 (34.57%)  
 >3 cm 19,127 (58.84%) 2030 (65.76%) 2720 (84.68%) 4130 (65.43%)  
Radiation therapy      < 0.001*
 No received 32,457 (99.85%) 3064 (99.25%) 3126 (97.32%) 6280 (99.49%)  
 Received 49 (0.15%) 23 (0.75%) 86 (2.68%) 32 (0.51%)  
Chemotherapy      < 0.001*
 No received 32,367 (99.57%) 3071 (99.48%) 3048 (94.89%) 6252 (99.05%)  
 Received 139 (0.43%) 16 (0.52%) 164 (5.11%) 60 (0.95%)  
Scope of lymph node      < 0.001
 None 30,254 (93.07%) 2910 (94.27%) 2759 (85.9%) 5908 (93.6%)  
 1–3 regional lymph nodes removed 1466 (4.51%) 131 (4.24%) 299 (9.31%) 756 (4.40%)  
 4 or more regional lymph nodes removed 786 (2.42%) 46 (1.49%) 154 (4.79%) 19,738 (2.00%)  
Surgey of primary site      < 0.001
 No operation 773 (2.38%) 517 (16.75%) 606 (18.87%) 944 (14.96%)  
 Local tumour destruction/excision 1555 (4.78%) 202 (6.54%) 101 (3.14%) 440 (6.97%)  
 partly nephrectomy 13,940 (42.88%) 857 (27.76%) 611 (19.02%) 1809 (28.66%)  
 total nephrectomy 16,238 (49.95%) 1511 (48.95%) 1894 (58.97%) 3119 (49.41%)  
  1. *Differences were evaluated by Fisher’s exact test
  2. Abbreviations: CCD cardiovascular and cerebrovascular death, KCD kidney cancer death, OE other events, AJCC American Joint Committee on Cancer
\